A BMC Medicine study reports that intranasally delivered recombinant BMP2/6 proteins slowed dopaminergic neuron degeneration in mouse models of Parkinsonian pathology while improving motor performance. The approach is designed to reach the brain via the nose, aiming to preserve dopamine neurons rather than treat symptoms after loss has occurred. The findings support further exploration of BMP2/6 as a potential neuroprotective modality and add to a growing pipeline of brain-delivery strategies that try to modulate disease-relevant pathways early.